Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 88fludarabine phosphate 77Busulfan 56Tacrolimus 54Mycophenolic Acid 54Antilymphocyte Serum 48Peripheral Blood Stem Cell Transplantation 46Filgrastim 42Melphalan 41Cyclosporine 39Whole-Body Irradiation 38fludarabine 36Radiotherapy 32Methotrexate 28Cord Blood Stem Cell Transplantation 25Methylprednisolone 24Alemtuzumab 17Etoposide 16Thiotepa 15Rituximab 14Cytarabine 14thymoglobulin 13Granulocyte Colony-Stimulating Factor 12Stem Cell Transplantation 10sargramostim 9Sirolimus 9Flow Cytometry 9Psychiatric Rehabilitation 8Prednisone 7Mesna 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × pasireotide × Myeloid × Clear all
NCT02215070 2021-11-17

Pasireotide in Prevention of GI Toxicity

Duke University

Phase 2 Completed
37 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡